Monitoring low-grade gliomas using blood samples
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
This study is testing if analyzing blood samples can help monitor patients with low-grade brain tumors for signs of recurrence better than current MRI methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Caen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Caen) |
| Trial ID | NCT06610851 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with grade 2 and 3 diffuse gliomas, which are common primary brain tumors. It aims to improve monitoring for tumor recurrence by analyzing circulating microRNA (miRNA) in blood samples, as current MRI methods are insufficient for early detection of recurrence. The study will involve patients who have undergone surgery at Caen University Hospital and will track their health outcomes over time. By utilizing blood samples, the researchers hope to develop a more effective monitoring tool for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults who have been diagnosed with grade 2 or 3 diffuse gliomas and have undergone surgical treatment at Caen University Hospital.
Not a fit: Patients with grade 1 or grade 4 gliomas, as well as those who have undergone biopsy or are minors, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of tumor recurrence in patients with low-grade gliomas, potentially improving treatment outcomes.
How similar studies have performed: While the use of circulating miRNA as a biomarker is a relatively novel approach, similar studies have shown promise in other cancer types, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Suffered from a grade 2-3 diffuse glioma * Surgery in the neurosurgery department of Caen University Hospital * Patient affiliated to a social security scheme * Patient followed at Caen University Hospital * No opposition from the patient Exclusion Criteria: * Patients who have undergone biopsy (lack of material for the study, limited value of monitoring for these patients without surgical excision) * Patients with grade 1 circumscribed glioma * Patients with grade 4 glioma * Other non-glial histologies, glioneuronal histology * Minor patients * Patient not affiliated to a social security scheme * Major under guardianship or protected
Where this trial is running
Caen
- Arthur LECLERC — Caen, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.